A new Transparency Market Research report states that the Europe platelet rich plasma market
stood at US$42.1 mn in 2013 and is predicted to reach US$ 87.2 mn in
2022. It is expected to expand at a CAGR of 8.30% from 2014 to 2022. The
title of the report is, “Platelet Rich Plasma Market – Europe Industry
Analysis, Size, Share, Growth, Trends & Forecast 2014 – 2022”.
According to the report, the platelet
rich plasma market in Europe is driven by the rising incidence of sports
injuries; diseases including orthopedic diseases, neurological
diseases, cardiovascular diseases; and obesity. In addition, the growing
geriatric population being more prone to surgeries and injuries has
also boosted the market. Furthermore, factors such as the launch of
numerous devices for the preparation of platelet rich plasmas and the
increasing awareness about the platelet rich plasma therapy and its
benefits have also impacted the market positively. On the other hand,
the factors such as the soaring costs of therapies and devices and the
chances of treatment failures are amongst the key factors that may
impede the growth of the market.
On the basis of type, the platelet rich
plasma market in Europe is segmented into pure-platelet rich plasma
(P-PRP), leukocyte-platelet rich fibrin (L-PRF), and leukocyte-platelet
rich plasma (L-PRP). Amongst these, the segment of P-PRP led the market
in 2013 and constituted a share of 70.8% in the market in Europe. This
is owing to the rich platelet content of P-PRP. On the other hand, the
segment of L-PRF is anticipated to experience the fastest growth rate in
the forecast horizon owing to its benefits such as ease of preparation,
reduced healing time of wounds, and cost-effectiveness, etc.
On the basis of origin, the market is
segmented into homologous, autologous, and allogenic. Amongst these, in
2013, the segment of autologous led the platelet rich plasma market in
Europe. On the other hand, the segment of allogenic platelet rich plasma
will also grow owing to its requirement in patients diagnosed with
blood disorders such as hemocytopenia and leukemia with a low count of
platelets in the blood.
On the basis of application, the market
is segmented into cosmetic surgery, orthopedic surgery, general surgery,
neurosurgery, and other surgeries such as cardiothoracic, urological,
and periodontal. Amongst these, in 2013, the orthopedic surgery
application segment led the market and represented 38.3% in the market.
This is due to the increasing geriatric population and the rising count
of sports and orthopedic injuries in Europe. In addition, platelet rich
plasmas are also widely used in cosmetic surgeries in facelift
treatments and facial aesthetics within the European region.
Geographically, the platelet rich plasma
market in Europe is segmented into Italy, the UK, France, Spain,
Germany, and Rest of Europe. Amongst these, the UK held the largest
share in the market in 2013 owing to the increasing prevalence of
reconstructive and orthopedic procedures in the country. In addition,
the rising inclination towards platelet rich plasma therapies for sports
injuries will also augment the development of the market in the UK.
The prime players dominant in the market
are Arthrex, Inc., EmCyte Corporation, Biomet, Inc., AdiStem Ltd, and
Medira Ltd., among others.
No comments:
Post a Comment